Researcher Profiles

Return to member profile

Elizabeth A. Poplin, MD

Publications since 2011

Poplin, E. Wasan, H. Rolfe, L. Raponi, M. Ikdahl, T. Bondarenko, I. Davidenko, I. Bondar, V. Garin, A. Boeck, S. Ormanns, S. Heinemann, V. Bassi, C. Evans, T. R. Andersson, R. Hahn, H. Picozzi, V. Dicker, A. Mann, E. Voong, C. Kaur, P. Isaacson, J. Allen, A. Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. J Clin Oncol, 31:4453-4461, . (PMID: 24220555)

Mita, M. M. Poplin, E. Britten, C. D. Tap, W. D. Rubin, E. H. Scott, B. B. Berk, L. Rivera, V. M. Loewy, J. W. Dodion, P. Haluska, F. Sarantopoulos, J. Mita, A. Tolcher, A. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol, 24:1104-1111, . (PMID: 23211938)

Chhabra, S. Wise, S. Maloney-Patel, N. Rezac, C. Poplin, E. Adenocarcinoma associated with tail gut cyst. J Gastrointest Oncol, 4:97-100, . (PMID: 23450681, PMCID: PMC3562636)

Rocha-Lima, C. M. Bayraktar, S. Macintyre, J. Raez, L. Flores, A. M. Ferrell, A. Rubin, E. H. Poplin, E. A. Tan, A. R. Lucarelli, A. Zojwalla, N. A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer, 118:4262-4270, . (PMID: 22294459)

Moss, R. A. Moore, D. Mulcahy, M. F. Nahum, K. Saraiya, B. Eddy, S. Kleber, M. Poplin, E. A. A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Gastrointest Cancer Res, 5:77-83, . (PMID: 22888387, PMCID: PMC3415717)

Saraiya, B. Chugh, R. Karantza, V. Mehnert, J. Moss, R. A. Savkina, N. Stein, M. N. Baker, L. H. Chenevert, T. Poplin, E. A. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, 30:258-265, . (PMID: 20697775)

Tunceroglu, A. Park, J. H. Balasubramanian, S. Poppe, M. Anker, C. J. Poplin, E. Moss, R. A. Yue, N. J. Carpizo, D. Gannon, C. J. Haffty, B. G. Jabbour, S. K. Dose-painted intensity modulated radiation therapy improves local control for locally advanced pancreas cancer. ISRN Oncol, 2012:572342, . (PMID: 23119186, PMCID: PMC3483817)

Jabbour, S. K. Patel, S. Herman, J. M. Wild, A. Nagda, S. N. Altoos, T. Tunceroglu, A. Azad, N. Gearheart, S. Moss, R. A. Poplin, E. Levinson, L. L. Chandra, R. A. Moore, D. F. Chen, C. Haffty, B. G. Tuli, R. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol, 2012:891067, . (PMID: 22934164, PMCID: PMC3425793)

Mehnert, J. M. Tan, A. R. Moss, R. Poplin, E. Stein, M. N. Sovak, M. Levinson, K. Lin, H. Kane, M. Gounder, M. Lin, Y. Shih, W. J. White, E. Rubin, E. H. Karantza, V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther, 10:1509-1519, . (PMID: 21680752, PMCID: PMC3155243)